drug · gene
brexucabtagene autoleucel
Phase 2updated 3mo agoby $GILD GILEAD SCIENCES, INC.🔗 ChEMBL
Phase 2community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with an approval for mantle cell lymphoma and 2 investigational indications.
targets
B-lymphocyte antigen CD19
all catalysts(0)
nothing on the calendar yet
Trials studying brexucabtagene autoleucel
- phase2Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- —Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
- phase2Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- phase2Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- phase2Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
- phase2Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
- EP1A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
- —Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that